Berlin Heals Launches Groundbreaking International C-MIC IV Study for Heart Failure Treatment
Berlin Heals Initiates Pioneering C-MIC IV Clinical Study
Berlin Heals Holding AG, a clinical-stage medical technology company, has taken a significant step in heart failure treatment by starting an international randomized, double-blind, placebo-controlled study known as C-MIC IV. This initiative follows the promising results from their previous study, C-MIC III, which focused on a less invasive implantation procedure conducted on an outpatient basis in catheter labs.
The C-MIC IV study marks a crucial milestone as it represents the first assessment of microcurrent therapy through a rigorous double-blind, placebo-controlled format. In this study, 60 patients from six European countries—Spain, Belgium, the Netherlands, Denmark, Serbia, and Bosnia and Herzegovina—will participate. To qualify, participants must suffer from symptomatic heart failure with a reduced ejection fraction greater than 20%, regardless of whether it is ischemic or non-ischemic in nature. This broadened inclusion criteria reflects a significant expansion of the target population when compared to earlier trials.
All participating patients will receive an implantable device to deliver the microcurrent therapy, although they will remain unaware of whether the device is active or inactive, ensuring the integrity of the trial's design. The initial patient was treated in Kragujevac, Serbia, by Dr. Miodrag Sreckovic, the head of interventional cardiology at the local university hospital. This significant event highlights not only the potential for innovation in heart failure management but also the collaborative efforts across European nations to enhance patient outcomes.
John Brumfield, the CEO of Berlin Heals, expressed the importance of this study, stating, “The commencement of the international C-MIC IV study is a pivotal moment for Berlin Heals as we continue to build a solid evidence base for this novel therapy.” Similarly, Dr. Faouzi Kallel, a scientist at Berlin Heals, emphasized that the C-MIC IV study is the second randomized trial dedicated to examining the safety and efficacy of microcurrent therapy, which will inform the design of their planned investigational device exemption (IDE) study.
Conducting randomized double-blind studies presents unique challenges, particularly with implantable medical devices where blinding is crucial. However, Stefan Anker, the global principal investigator and a professor of medicine at Charité, noted the inherent advantages of microcurrent therapy: “Since patients cannot perceive the microcurrent therapy, it allows us to obscure treatment assignments effectively from assessing physicians.”
Berlin Heals Holding AG, established in 2014, focuses on developing groundbreaking medical technologies. Their proprietary C-MIC technology delivers a consistent electric microcurrent to the heart, generating localized electric fields aimed at enhancing heart functionality. Preliminary clinical findings suggest that this approach may lead to early and sustained improvements in patients experiencing chronic heart failure.
With C-MIC IV now underway, Berlin Heals is set to expand its clinical experience with microcurrent technology, increasing its participant count to over 120 heart failure patients. The outcome of this study could pave the way for transformative advancements in the management of heart failure, potentially offering hope to countless individuals suffering from this debilitating condition.